Oncology Institute (DFPH) Non-Current Deferred Tax Liability (2020 - 2025)

Oncology Institute (DFPH) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $7.8 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability rose 24171.88% year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (up 24171.88% YoY) and the FY2025 annual result came in at $7.8 million, up 24171.88% from the prior year.
• Non-Current Deferred Tax Liability advanced to $7.8 million in Q4 2025, from $32000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $10.2 million in Q4 2023 to a low of $32000.0 in Q1 2024.
• A 5-year average of $1.4 million and a median of $108000.0 in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability plunged 99.69% — and 2025, when it surged 24171.88%.
• Tracing DFPH's Non-Current Deferred Tax Liability over 5 years: stood at $371000.0 in 2021, then sank by 70.89% to $108000.0 in 2022, then jumped by 9353.7% to $10.2 million in 2023, then sank by 99.69% to $32000.0 in 2024, then surged by 24171.88% to $7.8 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $7.8 million (Q4 2025), $32000.0 (Q1 2025), and $32000.0 (Q4 2024), per Business Quant data.